Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method
- 1 January 1998
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 36 (1) , 153-156
- https://doi.org/10.1128/jcm.36.1.153-156.1998
Abstract
Trailing endpoints remain a problem in antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NCCLS) method. For isolates for which trailing endpoints are found, MICs of ≤1 μg/ml at 24 h and of >64 μg/ml at 48 h are usually observed. In a study of human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis, we identified three patients with multiple serial isolates for which trailing endpoints were observed with fluconazole. At 24 h, MICs were generally ≤1 μg/ml by both broth macro- and microdilution methods. However, at 48 h, MICs were >64 μg/ml, while the organism remained susceptible by agar dilution testing with fluconazole. Most episodes of oropharyngeal candidiasis with trailing-endpoint isolates responded to doses of fluconazole as low as 100 mg/day. Two patients had both susceptible and trailing-endpoint isolates by NCCLS broth macro- and microdilution testing; these isolates were found to be the same strain by pulsed-field gel electrophoresis using restriction fragment length polymorphisms. Another patient had two different strains, one for which trailing endpoints were observed and one which was susceptible at 48 h. Trailing endpoints may be seen with selected isolates of a strain or may be a characteristic finding for most or all isolates of a strain. In addition, with isolates for which trailing endpoints are observed, reading the endpoint for the NCCLS method at 24 h may be more appropriate.Keywords
This publication has 15 references indexed in Scilit:
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicansJournal of Clinical Microbiology, 1996
- Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative studyAntimicrobial Agents and Chemotherapy, 1996
- Simple method for detecting fluconazole-resistant yeasts with chromogenic agarJournal of Clinical Microbiology, 1996
- Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870Journal of Clinical Microbiology, 1995
- Resistance of Candida albicans to Fluconazole During Treatment of Oropharyngeal Candidiasis in a Patient with AIDS: Documentation by In Vitro Susceptibility Testing and DNA Subtype AnalysisClinical Infectious Diseases, 1994
- Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1Antimicrobial Agents and Chemotherapy, 1993
- Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-testJournal of Clinical Microbiology, 1991
- Minimum Bactericidal Concentration of Sulfamethoxazole-Trimethoprim for Haemophilus influenzae : Correlation with ProphylaxisAntimicrobial Agents and Chemotherapy, 1978
- The Determination of Sulfonamide Susceptibility of BacteriaChemotherapy, 1964